Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours By Ogkologos - July 21, 2025 456 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Survival According Circulating Tumour DNA Status in the Study of Adjuvant... December 10, 2020 Couple Buys Customized SUV To Give Free Rides To Critically Ill... September 11, 2019 Camrelizumab Plus Rivoceranib Improves Survival Compared with Sorafenib in First-Line Treatment... August 2, 2023 3-in-1 Approach Helps Women in Rural Areas Get Cancer Screenings June 1, 2023 Load more HOT NEWS ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March Virtual Reality Could Reduce Stress for Chemo Patients, Improving Cancer Outcomes ESMO Asia Congress 2023, 1-3 December 2023, Singapore A New Online Tool Predicts RFS and OS Probabilities in Patients...
